Aurinia Appoints Max Colao as Chief Commercial Officer and Expands U.S. Commercial Leadership Team Feb 25, 2020
Aurinia Pharmaceuticals to Present at the 9th Annual SVB Leerink Global Healthcare Conference Feb 21, 2020
Aurinia Closes US$191.7 Million Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Common Shares Dec 12, 2019
Aurinia Announces Positive AURORA Phase 3 Trial Results Demonstrating Voclosporin Superiority Over Standard of Care in Lupus Nephritis Dec 4, 2019
Aurinia Completes Voclosporin Drug-Drug Interaction Study Demonstrating No Clinically Significant Interaction With Mycophenolate Mofetil Nov 7, 2019
